FDA s Gastroenterology and Urology Devices Panel unanimously recommended approval of Medical Enterprises Synergo combination product for prevention of bladder cancer recurrence. Conditions of approval include a one-year post-approval study to further assess its safety in the US population, development of labeling specifically stating that the device should not be used in patients with low-risk disease, a physician training program, and distribution of patient guides with the device. (Health News Daily)
More info on this treatment which uses Mitomycin and hyperthermia, and is approved in Europe since '05:
blcwebcafe.org/content/view/106/116/lang,english/